Lite Strategy, Inc. (LITS)
NASDAQ · Manufacturing · Pharmaceutical preparations
$1.52+$0.0861 (+6.02%) on the dayAs of the close; data may be delayed.
LITS price, last 12 months
Key stats
- Previous close
- $1.43
- Open
- $1.48
- Day range
- $1.37 – $1.56
- 52-week range
- $0.6888 – $2.97
- Volume
- 2.3M
- Avg volume (20 days)
- 882.2K
- Market cap
- $49.0M
Performance
1W+34.2%
1M+52.7%
3M+68.8%
6M+30.7%
YTD+14.9%
1Y−43.9%
vs S&P 500, 1Y−60.6 pts
Technicals and fundamentals
About Lite Strategy, Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $49.0M